Kromek announces strong H2 2025 results, CBRN detection revenue doubles
Kromek Group, a leading British developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, has announced its unaudited, interim results for the six months ended 31 October 2025.
Revenue increased substantially to £15.0m, compared to £3.7m in H1 2025, and CBRN detection revenue more than doubled to £4.3m, compared to £2.0m in H1 2025. The company's profit before tax increased to £3.1m after a seeing a loss of £5.7m in the first half of last year.
Announcing the interim, unaudited results on its website, Kromek said that growth in the CBRN sector was driven by executing their strategy to secure key government customers and expand distributor networks, alongside market recovery.
The company noted an initial order worth £1.7m received under UK Government’s Radiological Nuclear Detection Framework for the their nuclear security products, as well as a £250,000 contract with the UK Government's Defence Science and Technology Laboratory for the development of novel methods of enhancing the detection of biological agents and incidents. Kromek also received new CBRN detection orders from global customers, including from Europe, the US, Japan, Canada and Australasia.
"Growing global focus on national security"
Dr Arnab Basu, CEO of Kromek, said: “We are pleased with the strong performance delivered in the first half of the year, with growth achieved across both advanced imaging and CBRN detection. Sales in our CBRN segment more than doubled during the period, reflecting the growing global focus on national security and the increasing adoption of our market-leading technologies.
“Looking ahead to the second half of the year, with robust customer engagement and a good order book, we expect the momentum achieved in H1 to continue. As a result, we remain on track to deliver a fullyear performance in line with market expectations, supported by focused execution of our strategy and the continued demand for our innovative technologies.”
According to information supplied by Kromek Group, the company provides nuclear radiation detection solutions to the global homeland defence and security market. Their compact, handheld, high-performance radiation detectors, based on advanced scintillation technology, are primarily used to protect critical infrastructure and urban environments from the threat of 'dirty bombs'.
The Group is also developing bio-security solutions in the CBRN detection segment consisting of fully automated and autonomous systems to detect a wide range of airborne pathogens.
